BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sintbilo (Tafolecimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sintbilo (Tafolecimab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07341958-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sintbilo (Tafolecimab): Phase na readout est. (NCT07341958)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase na\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: INtensive liPid-lowering Therapy for Acute High-risk 
 IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tafolecimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07341958
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014215-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT07014215)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: PD-1 Combined With Be
 vacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Pr
 ogressed After Anti- PD- 1/L1 Therapy\nEstimated primary completion: May 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tafolecimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07014215
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT06421298)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: A Prospective\, Singl
 e-arm\, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Taf
 olecimab and Sintilimab Combined With Chemotherapy in Patients With Advanc
 ed or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Fai
 lure of First-line Immunotherapy.\nEstimated primary completion: 30 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tafolecimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06421298
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061535-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT07061535)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: Sintilimab Combined W
 ith Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Sta
 ge Small Cell Lung Cancer\nEstimated primary completion: 1 August 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tafolecimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07061535
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621562-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT07621562)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: Tafolecimab Combined 
 With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer\nEstim
 ated primary completion: 1 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tafolecimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07621562
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683131-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sintbilo (Tafolecimab): Phase 4 readout est. (NCT06683131)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 4.\nStudy: Effectiveness of Prop
 rotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Bef
 ore Percutaneous Coronary Intervention on Acute Myocardial Infarction Pati
 ents\nEstimated primary completion: 30 November 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tafolecimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06683131
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096909-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Sintbilo (Tafolecimab): Phase 4 readout est. (NCT06096909)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 4\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Early Initiation of Tafolecimab for Patients With Acut
 e Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chines
 e Population\nEstimated primary completion: 1 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tafolecimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06096909
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT07717242)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: Sun Yat-Sen Treatment
  Strategy for Enhancing Response in Muscle-invasive Bladder Cancer\nEstima
 ted primary completion: 30 June 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tafolecimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07717242
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840677-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Sintbilo (Tafolecimab): Phase 2 readout est. (NCT07840677)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 2.\nStudy: Tafolecimab Combined 
 With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Adva
 nced Colon Cancer\nEstimated primary completion: 20 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tafolecimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07840677
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686796-1052@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Sintbilo (Tafolecimab): Phase 3 readout est. (NCT07686796)
DESCRIPTION:Sintbilo (Tafolecimab)\, phase 3.\nStudy: Anti-PCSK9 Antibody T
 afolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Che
 moradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospectiv
 e\, Multicenter\, Randomized\, Open-Label\, Parallel-Controlled Trial\nEst
 imated primary completion: 1 January 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tafolecimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07686796
URL:https://assetmemo.bio/drug/tafolecimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
